Comparison of Bevacizumab, Ranibizumab, and Pegaptanib in Vitro: Efficiency and Possible Additional Pathways

Investigative Ophthalmology and Visual Science - United States
doi 10.1167/iovs.08-2055
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Association for Research in Vision and Ophthalmology (ARVO)

Related search

Comparison of Intravitreal Ranibizumab and Bevacizumab Treatment for Retinopathy of Prematurity

Arquivos Brasileiros de Oftalmologia
MedicineOphthalmology
2015English

Comparison of the Effect Between Pegaptanib and Ranibizumab on Exudative Age-Related Macular Degeneration With Small Lesion Size

Clinical Ophthalmology
Ophthalmology
2012English

Systemic Pharmacokinetics and Pharmacodynamics of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab

Retina
MedicineOphthalmology
2017English

Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration

Ophthalmology
Ophthalmology
2014English

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

Ophthalmology
Ophthalmology
2016English

İlk Üç Doz Sonrası Stabilizasyon Oranları Açısından Ranibizumab Ve Pegaptanib Sodyum Monoterapilerinin Karşılaştırılması

Turk Oftalmoloiji Dergisi
Ophthalmology
2012English

Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy

Pharmaceutical Research
Organic ChemistryBiotechnologyMolecular MedicinePharmacologyPharmaceutical Science
2016English

Treatment of Intractable Diabetic Macular Edema With Pegaptanib Versus Bevacizumab, Both in Combination With Dexamethasone

Kansas Journal of Medicine
2012English

Corneal Neovascularization and the Utility of Topical VEGF Inhibition: Ranibizumab (Lucentis) vs Bevacizumab (Avastin)

Ocular Surface
Ophthalmology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy